BridgeBio Oncology Therapeutics, Inc. Restricted Cash and Cash Equivalents
BridgeBio Oncology Therapeutics, Inc. (BBOT) had Restricted Cash and Cash Equivalents of $408.87 million as of 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Balance Sheet › Assets › Restricted Cash and Cash Equivalent
us-gaap:RestrictedCashAndCashEquivalents · last filed 2025-11-12
- 2025-09-30: Restricted Cash and Cash Equivalents $408.87M.
- 2024-12-31: Restricted Cash and Cash Equivalents $30.98M.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2025-09-30 | $408.87M 10-Q · filed 2025-11-12 |
| 2024-12-31 | $30.98M 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |